A Comprehensive Monograph on Penequinine (Penehyclidine): Pharmacology, Clinical Evidence, and Therapeutic Potential

Executive Summary

Penequinine, more commonly encountered in its clinical hydrochloride salt form as Penehyclidine (DrugBank ID: DB16287), is a potent anticholinergic agent developed and primarily utilized in China. It represents a significant pharmacological advancement over traditional anticholinergics like atropine. The molecule's therapeutic efficacy is rooted in a dual mechanism of action that combines selective antagonism of muscarinic (M1, M3) and nicotinic acetylcholine receptors with a distinct, secondary anti-inflammatory and cytoprotective function mediated through the negative regulation of the Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-kB) signaling pathways. This unique pharmacological profile translates into a broad spectrum of clinical applications, most notably in the management of acute organophosphorus pesticide poisoning (AOPP), where it has demonstrated marked superiority over atropine in large-scale meta-analyses, significantly reducing mortality, morbidity, and adverse effects.

Beyond its role as a critical antidote, Penehyclidine is established as a preanesthetic medication and has proven effective in perioperative settings, particularly for the prevention of postoperative nausea and vomiting (PONV) and postoperative pulmonary complications. Its bronchodilatory and anti-inflammatory properties have positioned it as a promising investigational candidate for the treatment of chronic obstructive pulmonary disease (COPD). Furthermore, preclinical and emerging clinical data suggest significant organ-protective effects across the heart, lungs, brain, and other tissues, driven by its ability to mitigate ischemia-reperfusion injury and inflammatory insults. Despite a robust body of clinical evidence from China supporting its efficacy and superior safety profile, Penequinine has not undergone regulatory review or approval by major Western agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This report provides a comprehensive monograph on the chemical properties, multifaceted pharmacology, clinical evidence, and future potential of this strategically important therapeutic agent.

Chemical Identity and Physicochemical Properties

A precise understanding of the chemical and physical characteristics of Penequinine is fundamental to interpreting its pharmacological behavior, pharmacokinetic profile, and formulation as a therapeutic agent. The molecule is identified by several names and numerical codes across various chemical and pharmacological databases.

Nomenclature and Identifiers

To ensure clarity and prevent ambiguity, the compound is catalogued under the following identifiers:

• Generic Names: The most common generic names for the active molecule are Penequinine and Penehyclidine.[1] The latter term is often used interchangeably for the base and its hydrochloride salt.
• Synonyms: Additional synonyms found in the literature include Penequine and Penethequinine.[2]
• DrugBank Accession Number: The compound is uniquely identified in the DrugBank database as DB16287.[1]
• CAS Numbers: Two distinct Chemical Abstracts Service (CAS) numbers are associated with the compound, corresponding to its base and salt forms:
• 87827-02-9: This number identifies the free base form, Penequinine.[2]
• 151937-76-7: This number identifies the hydrochloride salt, Penehyclidine hydrochloride (PHC), which is the stable, water-soluble form used in clinical formulations and most research studies.[7]
• Other Identifiers: The molecule is further catalogued under various international and internal coding systems, including:
• UNII: 353CX8CSHD.[2]
• PubChem CID: 137356.[6]
• External IDs: M-8218 and P8018.[2]

Molecular Structure and Formula

Penequinine is a small molecule characterized by a complex, multi-ring structure.

• Chemical Formula: The molecular formula for the base molecule is C20​H29​NO2​.[2] The formula for the hydrochloride salt is C20​H30​ClNO2​.[7]
• IUPAC Name: The systematic name according to the International Union of Pure and Applied Chemistry (IUPAC) is 2-(1-Azabicyclo[2.2.2]oct-3-yloxy)-1-cyclopentyl-1-phenylethanol.[2] This name precisely describes its constituent parts: a phenyl group and a cyclopentyl group attached to a central carbon, which also bears a hydroxyl group and is connected via an ether linkage to the 3-position of a quinuclidine (1-azabicyclo[2.2.2]octane) ring system.
• Structural Representations: The molecule's two-dimensional structure can be represented by standard chemical notations:
• InChI: InChI=1S/C20H29NO2/c22-20(18-8-4-5-9-18,17-6-2-1-3-7-17)15-23-19-14-21-12-10-16(19)11-13-21/h1-3,6-7,16,18-19,22H,4-5,8-15H2.[2]
• SMILES: OC(COC1CN2CCC1CC2)(C1CCCC1)C1=CC=CC=C1.[2]

Physicochemical Profile

The physicochemical properties of Penequinine govern its absorption, distribution, metabolism, and excretion (ADME), as well as its ability to interact with biological targets. These properties, summarized in Table 1, reveal a molecule well-suited for its intended pharmacological roles.

• Molecular Weight: The average mass of the Penequinine base is 315.457 Da.[2] The hydrochloride salt has a molecular weight of 351.91 Da, reflecting the addition of hydrogen chloride.[7]
• Solubility and Lipophilicity: The molecule exhibits low aqueous solubility (0.046 mg/mL) but possesses significant lipophilicity, with a calculated logarithm of the partition coefficient (logP) of approximately 3.36.[2] This high lipophilicity is a critical feature, as it facilitates the molecule's ability to traverse lipid bilayers, including the blood-brain barrier. This structural characteristic is the direct determinant of the drug's potent central nervous system effects, a key clinical advantage over peripherally restricted anticholinergic agents. The presence of a tertiary amine within the quinuclidine ring system, combined with this high lipid solubility, allows Penequinine to readily access central cholinergic receptors, which is essential for counteracting the CNS symptoms of organophosphorus poisoning.[10]
• Ionization: With a strongly acidic pKa of 13.13 (attributable to the hydroxyl group) and a strongly basic pKa of 8.38 (attributable to the tertiary amine nitrogen), the molecule is predicted to carry a positive charge (Physiological Charge: 1) at physiological pH.[2] This ionization state is important for receptor binding and solubility.
• Medicinal Chemistry Compliance: Penequinine adheres to several empirical rules used to predict drug-likeness and favorable pharmacokinetic properties. It satisfies Lipinski's Rule of Five, the Ghose Filter, and Veber's Rule, suggesting a high probability of good membrane permeability and oral bioavailability.[2]

Table 1: Physicochemical Properties of Penequinine

Property	Penequinine (Base)	Penehyclidine Hydrochloride (Salt)	Source(s)
Chemical Formula	C20​H29​NO2​	C20​H30​ClNO2​	2
Average Molecular Weight	315.457 Da	351.91 Da	2
CAS Number	87827-02-9	151937-76-7	2
IUPAC Name	2-(1-Azabicyclo[2.2.2]oct-3-yloxy)-1-cyclopentyl-1-phenylethanol	N/A	2
Water Solubility	0.046 mg/mL	N/A	2
logP (Octanol/Water)	3.36	N/A	2
pKa (Strongest Acidic)	13.13	N/A	2
pKa (Strongest Basic)	8.38	N/A	2
Physiological Charge (pH 7.4)	+1	+1	2
Rule of Five Compliance	Yes	N/A	2

Pharmacology and Mechanism of Action

Penehyclidine exhibits a sophisticated, dual mechanism of action that distinguishes it from conventional anticholinergic drugs. It functions not only as a potent antagonist of cholinergic receptors but also as a modulator of key inflammatory pathways, accounting for its broad therapeutic effects and organ-protective properties.

Primary Mechanism: Anticholinergic Activity

The principal pharmacological action of Penehyclidine is the blockade of acetylcholine (ACh) signaling at both muscarinic and nicotinic receptors. This comprehensive antagonism is central to its use as an antidote and preanesthetic agent.

• Muscarinic Receptor Antagonism: Penehyclidine is a selective antagonist of M1 and M3 muscarinic acetylcholine receptors.[8] Blockade of M1 receptors, which are prevalent in the central nervous system and autonomic ganglia, contributes to its central effects and its ability to modulate ganglionic transmission. Antagonism of M3 receptors, located on smooth muscle and secretory glands, is responsible for its potent effects in reducing glandular secretions (e.g., saliva, bronchial mucus), relaxing airway and gastrointestinal smooth muscle, and causing mydriasis.[10] While some sources also mention M2 receptor antagonism, this effect appears to be significantly weaker, which constitutes a major clinical advantage.[10]
• Nicotinic Receptor Antagonism: A critical feature that differentiates Penehyclidine from pure antimuscarinic agents like atropine is its ability to also antagonize nicotinic acetylcholine receptors (N receptors).[10] This dual M and N receptor blockade allows it to counteract the full spectrum of symptoms in cholinergic crisis, such as that seen in AOPP. While its antimuscarinic action controls symptoms like bradycardia, salivation, and bronchospasm, its antinicotinic action addresses symptoms mediated by nicotinic receptors at the neuromuscular junction, such as muscle fasciculations, fibrillation, and weakness.[11]
• Central and Peripheral Effects: As established by its physicochemical properties, Penehyclidine readily crosses the blood-brain barrier, enabling it to exert potent anticholinergic effects within the central nervous system.[10] This is crucial for managing the CNS toxicity of organophosphorus compounds (e.g., seizures, coma, respiratory depression) and contributes to its antiemetic properties by acting on the chemoreceptor trigger zone and vestibular nuclei.[11]

Secondary Mechanism: Anti-inflammatory and Cytoprotective Pathways

Beyond its classical anticholinergic activity, Penehyclidine possesses a novel mechanism of action involving the modulation of innate immunity and cellular stress pathways. This activity underlies its observed organ-protective and disease-modifying potential.

• TLR4/NF-kB Signaling Inhibition: Penehyclidine is a negative regulator of Toll-like receptor 4 (TLR4), a key pattern recognition receptor of the innate immune system, and its downstream signaling cascade involving nuclear factor-kappa B (NF-kB).[9] NF-kB is a master transcription factor that orchestrates the expression of numerous pro-inflammatory genes. By inhibiting this pathway, Penehyclidine effectively dampens the inflammatory response to various stimuli.
• Cytokine Modulation: The inhibition of NF-kB activation leads to a marked suppression in the production and release of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6).[8] This anti-inflammatory effect has been demonstrated in vitro in human bronchial epithelial cells and in vivo in animal models of acute lung injury and COPD, where it alleviates pulmonary inflammation and edema.[8]
• Cell Survival and Protective Pathways: Preclinical research has revealed that Penehyclidine can activate pro-survival signaling pathways. In cardiomyocyte cell lines, it has been shown to activate the Akt/GSK-3β pathway, a critical cascade involved in promoting cell survival and protecting against apoptosis, particularly in the context of anoxia/reoxygenation injury.[8] It has also been observed to promote autophagy, a cellular process for clearing damaged components, in response to inflammatory stimuli.[8]

The convergence of these two distinct mechanisms—anticholinergic and anti-inflammatory—is highly significant. It suggests that Penehyclidine may function as a disease-modifying agent in conditions where both cholinergic dysregulation and inflammation are key pathophysiological drivers. For instance, in COPD, cholinergic hyperactivity promotes bronchoconstriction and mucus hypersecretion, while chronic inflammation driven by pathways like TLR4/NF-kB causes progressive lung tissue destruction.[15] A single molecule capable of targeting both axes could offer therapeutic benefits superior to those of traditional anticholinergics, which only provide symptomatic bronchodilation. This synergistic potential positions Penehyclidine for broader applications in various neuro-inflammatory disorders.

Comparative Pharmacology

Penehyclidine's pharmacological profile offers several distinct advantages over older, less selective anticholinergic agents like atropine and scopolamine, as detailed in Table 2.

• Superior Receptor Selectivity: The most significant advantage of Penehyclidine is its relative sparing of the M2 muscarinic receptor subtype.[10] M2 receptors are predominantly located in the heart and function as autoreceptors that mediate negative feedback on acetylcholine release, leading to a slowing of the heart rate. Atropine is a non-selective antagonist and potently blocks M2 receptors, which disinhibits the vagal brake on the heart, frequently causing significant and sometimes problematic tachycardia. By having a lower affinity for M2 receptors, Penehyclidine can achieve its desired therapeutic effects at M1 and M3 receptors with a substantially lower risk of inducing tachycardia, a key factor in its superior safety profile in critically ill patients.[10]
• Broader Spectrum of Action: As previously noted, Penehyclidine's dual antagonism of both muscarinic and nicotinic receptors provides more comprehensive therapeutic coverage in conditions of widespread cholinergic overstimulation, such as AOPP, compared to the purely antimuscarinic action of atropine.[10]

Table 2: Comparative Pharmacological Profile of Penequinine, Atropine, and Scopolamine

Feature	Penehyclidine Hydrochloride (PHC)	Atropine	Scopolamine
Primary Receptor Targets	M1, M3 Muscarinic; Nicotinic	Non-selective Muscarinic (M1-M5)	Non-selective Muscarinic (M1-M5)
M2 Receptor Affinity	Low / Sparing	High	High
Nicotinic Receptor Activity	Antagonist	None	None
CNS Penetration	High	Moderate	High
Primary Clinical Advantage	Reduced tachycardia (M2 sparing); Broader symptom control in AOPP (M+N antagonism)	Readily available, well-established	Potent antiemetic and sedative effects
Key Disadvantage	Limited global availability and regulatory approval	Significant tachycardia; Lacks nicotinic antagonism	High incidence of central side effects (sedation, confusion, hallucinations)

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Penehyclidine is characterized by rapid absorption and wide distribution, consistent with its use in acute settings and its ability to act on both central and peripheral targets.

• Absorption: Following intramuscular administration of a 1 mg dose in healthy human volunteers, Penehyclidine is rapidly absorbed into the systemic circulation. It can be detected in the blood as early as 2 minutes post-injection. The time to reach maximum plasma concentration (Tmax​) is approximately 34 minutes, with a corresponding peak concentration (Cmax​) of about 13.20 µg/L.[20] The drug is also administered orally for certain investigational uses, such as Parkinson's disease, which implies it possesses adequate oral bioavailability, though specific quantitative data are not available in the provided materials.[13]
• Distribution: Animal studies indicate that after absorption, Penehyclidine is distributed extensively throughout the body. The highest tissue concentrations are observed in the submandibular glands, a site rich in muscarinic receptors. High concentrations are also found in the lungs, spleen, intestines, heart, kidneys, and muscles.[20] This distribution pattern aligns well with its known sites of pharmacological action, including secretory glands, the respiratory tract, and the central nervous system.
• Metabolism: The specific metabolic pathways of Penehyclidine, including the cytochrome P450 (CYP) enzymes responsible for its biotransformation, are not detailed in the available research. This represents a significant knowledge gap that would be critical for assessing its potential for drug-drug interactions.
• Excretion: Penehyclidine and its metabolites are eliminated from the body primarily through renal and fecal routes. The elimination process is relatively efficient, with 94.17% of an administered dose being excreted within 24 hours.[20]

Clinical Evidence and Therapeutic Applications

The clinical utility of Penehyclidine has been extensively documented in China, where it is a standard-of-care agent for several conditions. Its efficacy is supported by numerous clinical trials, including large-scale meta-analyses.

Acute Organophosphorus Pesticide Poisoning (AOPP)

The most compelling and well-established application for Penehyclidine is as a first-line antidote for AOPP.

• Pathophysiology of AOPP: Organophosphorus compounds are potent, irreversible inhibitors of the enzyme acetylcholinesterase (AChE). Inhibition of AChE leads to a massive accumulation of acetylcholine at cholinergic synapses throughout the body, resulting in a state of continuous nerve stimulation known as a cholinergic crisis. This manifests as a toxidrome of muscarinic symptoms (salivation, lacrimation, urination, defecation, GI distress, emesis, bronchospasm, bradycardia), nicotinic symptoms (muscle fasciculations, cramping, weakness, paralysis), and central nervous system effects (confusion, seizures, coma, respiratory depression).[11]
• Meta-Analysis Evidence: A landmark systematic review and meta-analysis, encompassing 240 randomized controlled trials with a total of 20,797 subjects, provides definitive evidence of Penehyclidine hydrochloride's (PHC) superiority over atropine in the treatment of AOPP.[11] The key findings demonstrate statistically significant and clinically meaningful benefits for PHC across multiple endpoints:
• Superior Efficacy: Treatment with PHC was associated with a dramatic 80% reduction in the risk of mortality compared to atropine (Risk Ratio = 0.20). Patients in the PHC group also had significantly shorter hospital stays (Weighted Mean Difference = -3.89 days) and a 65% reduction in the overall incidence of complications (RR = 0.35).[11]
• Reduced Complications: The reduction in complications was observed across several critical domains, including lower rates of delayed polyneuropathy, intermediate syndrome, symptom rebound, and respiratory failure.[11]
• Faster Recovery: PHC treatment led to a more rapid clinical recovery, with significantly shorter times to disappearance of all major symptom clusters (muscarinic, nicotinic, and CNS). Furthermore, it accelerated the recovery of cholinesterase activity and reduced the duration of coma and the need for mechanical ventilation.[11]
• Pharmacological Rationale for Superiority: These profound clinical advantages are a direct consequence of Penehyclidine's unique pharmacology. Its ability to cross the blood-brain barrier allows it to directly counteract the life-threatening central effects of organophosphorus poisoning. Its dual antagonism of both muscarinic and nicotinic receptors provides comprehensive control over the entire spectrum of cholinergic symptoms, a feat that the purely antimuscarinic atropine cannot achieve.[11]

Perioperative and Anesthetic Applications

Penehyclidine is widely employed in the perioperative setting in China, leveraging its anticholinergic properties to improve surgical conditions and patient outcomes.

• Preanesthetic Medication: It is routinely used as a preanesthetic agent to reduce salivary and bronchial secretions, which can improve airway management and reduce the risk of aspiration. It also relaxes airway smooth muscle, prevents reflex bradycardia mediated by the vagus nerve during surgical manipulation, and can contribute to sedation.[10]
• Prevention of Post-Operative Nausea and Vomiting (PONV): Completed Phase 4 clinical trials have confirmed the efficacy of Penehyclidine for PONV prophylaxis.[1] For example, trial NCT04054479 demonstrated its effectiveness after strabismus surgery.[1] A meta-analysis of five RCTs (979 patients) further solidified this indication, showing that PHC significantly reduced the incidence of PONV within the first 24-72 hours post-surgery (RR = 0.64) and decreased the need for rescue antiemetic medications by more than 50% (RR = 0.46).[17]
• Prevention of Postoperative Pulmonary Complications (PPCs): The drug is under active investigation for the prevention of PPCs, as seen in clinical trial NCT02644876.[2] The therapeutic rationale is based on its ability to reduce airway secretions and its potent anti-inflammatory effects within the lungs, which may mitigate the pulmonary inflammation associated with surgery and anesthesia.

Investigational and Potential Future Applications

The dual pharmacological actions of Penehyclidine open up numerous avenues for future therapeutic development.

• Chronic Obstructive Pulmonary Disease (COPD): Penehyclidine is considered a highly promising candidate for COPD management. Its M3 receptor antagonism provides potent bronchodilation, while its ability to attenuate TLR-mediated inflammation addresses the underlying inflammatory pathology of the disease.[8] Animal models have shown that it can effectively alleviate the pulmonary inflammatory response during mechanical ventilation in rats with induced COPD.[8]
• Organ Protection: A growing body of evidence points to the significant organ-protective effects of Penehyclidine. These effects, mediated by its antioxidant, anti-apoptotic, and anti-inflammatory properties, have been observed in the heart, lungs, brain, kidneys, intestines, and liver.[10] It is being formally investigated in clinical trials for conditions such as acute lung injury and acute cerebral ischemia-reperfusion injury.[9]
• Septic Shock: Its capacity to improve microcirculation, inhibit the systemic release of inflammatory mediators, and protect vital organs from sepsis-induced damage suggests a potential therapeutic role in the complex management of septic shock.[10]
• Parkinson's Disease: The drug has been mentioned as a potential therapy for conditions involving cholinergic system dysregulation, such as Parkinson's disease, where it could help alleviate motor symptoms by rebalancing the dopamine-acetylcholine ratio in the brain.[13]

Table 3: Summary of Key Clinical Trials for Penequinine

ClinicalTrials.gov ID	Phase	Condition / Indication	Purpose	Status	Key Findings / Relevance
NCT04054479	4	Post Operative Nausea and Vomiting (PONV)	Prevention	Completed	Demonstrates efficacy of Penehyclidine for PONV prophylaxis after strabismus surgery.1
NCT02644876	4	Postoperative Pulmonary Complications	Prevention	Completed	Investigated the use of Penehyclidine inhalation to prevent pulmonary complications after surgery.2

Safety, Tolerability, and Toxicology

The safety profile of Penehyclidine is primarily defined by its anticholinergic mechanism, but it is distinguished by a favorable comparison to older agents, particularly atropine.

Adverse Effect Profile

• Common Side Effects: As expected for an anticholinergic agent, Penehyclidine is associated with class-specific side effects. The most frequently reported adverse event in clinical trials for PONV was dry mouth, which occurred significantly more often than in control groups (RR = 2.64).[17] Other common, dose-dependent effects include blurred vision, constipation, and urinary retention.[13]
• Dose-Dependent and Serious Side Effects: At higher doses, central nervous system effects can become more pronounced, potentially leading to dizziness, confusion, disorientation, hallucinations, delirium, and, in cases of significant overdose, coma.[13] A rise in body temperature (hyperthermia) due to inhibition of sweating and urinary retention are also risks associated with excessive dosage.[20]
• Comparative Safety: A cornerstone of Penehyclidine's clinical value is its superior safety and tolerability profile when compared directly to atropine for the treatment of AOPP. The comprehensive meta-analysis found that the Penehyclidine group had an 81% lower overall incidence of adverse reactions (RR = 0.19). Specifically, patients treated with Penehyclidine experienced significantly less blurred vision, thirst, urinary retention, fever, restlessness, and, most critically, tachycardia.[11] This reduced incidence of tachycardia is a direct clinical manifestation of its M2-receptor-sparing pharmacology and represents a major safety advantage in critically ill patients who may have compromised cardiovascular function.[10]

Contraindications and Precautions

Caution should be exercised when administering Penehyclidine to patients with pre-existing conditions that could be worsened by its anticholinergic effects. These include narrow-angle glaucoma (where it can increase intraocular pressure), myasthenia gravis (where it can exacerbate muscle weakness), prostatic hypertrophy (where it can precipitate acute urinary retention), and obstructive disorders of the gastrointestinal or genitourinary tracts.[13]

Toxicology Summary

Preclinical toxicology assessments have been performed to characterize the safety of Penehyclidine. Specific studies investigating embryo-fetal development toxicity in rats and fertility and early embryonic development toxicity in mice have been published.[9] However, the detailed results and findings of these studies were not available in the reviewed materials, indicating a need for access to the primary literature for a complete toxicological assessment. No information regarding the carcinogenicity or genotoxicity of Penequinine was found. It is crucial to note that information related to Phencyclidine (PCP) overdose is entirely irrelevant to Penequinine, as they are structurally and pharmacologically distinct compounds.[23] No specific data on Penequinine overdose was available, though the clinical presentation would be an exacerbation of its known anticholinergic effects.

Drug Interactions

• Additive Anticholinergic Effects: Penehyclidine is expected to have additive effects when co-administered with other medications possessing anticholinergic properties (e.g., tricyclic antidepressants, some antihistamines, other antimuscarinic agents), potentially increasing the risk of side effects like dry mouth, blurred vision, and urinary retention.
• CNS Depressants: Concomitant use with other central nervous system depressants, such as benzodiazepines, opioids, or alcohol, could result in additive sedation, dizziness, and cognitive impairment.[25]
• Pharmacokinetic Interactions: Drugs that alter gastric pH (e.g., proton pump inhibitors, antacids) or gastrointestinal motility could theoretically affect the rate and extent of absorption of orally administered Penehyclidine formulations.[13]

Dosage and Administration

Dosing regimens for Penehyclidine vary depending on the clinical indication and route of administration. The following dosages have been reported in clinical studies:

• Prevention of PONV: In clinical trials, Penehyclidine was administered intravenously either as a fixed dose of 0.5 mg or as a weight-based dose of 10 µg/kg (with a maximum dose of 0.5 mg).[17] In one protocol, a continuous intravenous infusion of 10 µg/kg was maintained over 48 hours via a postoperative analgesia pump.[17]
• Parkinson's Disease (Investigational): For potential use in Parkinson's disease, a suggested oral starting dose is 0.5 mg to 1 mg, administered once or twice daily. The dose would then be titrated according to the patient's clinical response and tolerability.[13]
• Acute Organophosphorus Pesticide Poisoning (AOPP): While specific, detailed dosing protocols for AOPP were not provided in the reviewed materials, treatment would invariably involve intravenous administration, likely beginning with a loading dose to rapidly achieve therapeutic concentrations, followed by a continuous infusion. The infusion rate would be carefully titrated based on the resolution of cholinergic signs and symptoms, such as control of secretions, heart rate, and mental status.

Regulatory Status and Development History

The development and regulatory trajectory of Penehyclidine is unique and largely confined to China, which has significant implications for its global accessibility.

Development History

Penehyclidine hydrochloride was developed by the Chinese Academy of Military Sciences.[10] It was synthesized as a novel anticholinergic agent derived from the natural alkaloid scopolamine. The context of its development by a military research institution strongly suggests that its initial purpose was strategic, likely as a more effective and safer antidote to nerve agent poisoning (e.g., soman) for military personnel, in addition to its clear application for civilian organophosphorus pesticide poisoning.[9] This origin explains the focus on creating a potent, centrally-acting agent with a superior safety profile compared to existing antidotes like atropine.

Global Regulatory Landscape

The regulatory status of Penehyclidine highlights a significant disparity between its use in China and its recognition elsewhere.

• China: The drug is fully approved and has been in widespread clinical use for many years. It is considered a standard-of-care medication for AOPP and is commonly used as a preanesthetic agent.[10]
• United States (FDA): There is no evidence that Penequinine or Penehyclidine has been submitted for review or approved by the U.S. FDA. It is categorized as an investigational drug in some U.S.-based databases.[2] The reviewed materials discussing FDA approvals for drugs with similar-sounding names, such as "penpulimab" or "sepiapterin," are unrelated to Penequinine.[27]
• European Union (EMA): Similarly, there are no records of Penehyclidine being approved by the European Medicines Agency.[3]

This regulatory landscape reveals a notable "translation gap." Despite the existence of compelling, large-scale clinical data from China demonstrating Penehyclidine's superiority over the global standard of care (atropine) for a life-threatening condition like AOPP, the drug remains unavailable in most of the world. This situation may be attributable to several factors, including a lack of commercial incentive or resources on the part of the original developer to pursue costly international registration, or the possibility that the existing data packages, while robust, may not meet the specific formatting and trial design requirements of Western regulatory bodies without supplementary studies. This leaves a clinically valuable and potentially life-saving medication inaccessible outside of its country of origin due to regulatory and commercial hurdles rather than a lack of evidence for its efficacy or safety.

Conclusion and Future Directions

Concluding Synthesis

Penequinine, in its clinical form Penehyclidine hydrochloride, is a pharmacologically sophisticated anticholinergic agent that represents a clear therapeutic advance over conventional drugs in its class. Its dual mechanism of action—combining selective M1/M3 and nicotinic receptor antagonism with a novel anti-inflammatory effect via TLR4/NF-kB inhibition—confers a unique profile of efficacy and safety. The clinical evidence, particularly from a large meta-analysis in acute organophosphorus pesticide poisoning, is unequivocal in establishing its superiority over atropine, demonstrating significant reductions in mortality, complications, and adverse events. Furthermore, its established role in perioperative medicine and its significant potential in treating chronic inflammatory conditions like COPD underscore its versatility. The pleiotropic, organ-protective effects observed in preclinical and emerging clinical studies suggest that its therapeutic applications may extend even further. Penehyclidine is a prime example of a highly effective therapeutic agent whose global health impact is currently limited by regional development and regulatory confinement.

Future Directions and Unanswered Questions

To realize the full global potential of Penehyclidine, several critical steps and areas of research must be pursued:

• Initiation of Western Clinical Trials: The most pressing need is for the design and execution of large-scale, multicenter, randomized controlled trials in North American and European patient populations. Validating the extensive findings from China under the rigorous guidelines of the FDA and EMA is the essential prerequisite for any future submission for regulatory approval in these regions.
• Elucidation of Mechanism of Action: While the dual mechanisms are established, further research is required to fully characterize the molecular interplay between its anticholinergic and anti-inflammatory effects. Investigating its potential in other diseases with a prominent neuro-inflammatory component (e.g., postoperative cognitive dysfunction, inflammatory bowel disease) is a logical next step.
• Comprehensive Pharmacokinetic Profiling: A complete characterization of Penehyclidine's metabolic fate, including the identification of specific CYP enzymes involved and a formal assessment of its potential for drug-drug interactions, is necessary. Detailed studies on its oral bioavailability and pharmacokinetics in special populations (e.g., renal or hepatic impairment) are also needed to optimize dosing and ensure safety.
• Addressing Global Health Needs: Given that organophosphorus pesticide poisoning is a major public health crisis in many developing nations, exploring pathways for making Penehyclidine more widely accessible should be a global health priority. This could involve collaborations with international health organizations or the pursuit of registration in other countries where the need is greatest.

Works cited

1. Penequinine, Penehyclidine Completed Phase 4 Trials for Post Operative Nausea and Vomiting (PONV) Prevention - DrugBank, accessed September 9, 2025, https://go.drugbank.com/drugs/DB16287/clinical_trials?conditions=DBCOND0076946&phase=4&purpose=prevention&status=completed
2. Penequinine, Penehyclidine: Uses, Interactions, Mechanism of ..., accessed September 9, 2025, https://go.drugbank.com/drugs/DB16287
3. Penequinine, Penehyclidine | MedPath, accessed September 9, 2025, https://trial.medpath.com/drug/14dd4aa9c0950a58/penequinine-penehyclidine
4. PENEQUININE | C20H29NO2 - ChemSpider, accessed September 9, 2025, https://www.chemspider.com/Chemical-Structure.121036.html
5. PENEQUININE, accessed September 9, 2025, https://www.drugfuture.com/gsrs/substance/353cx8cshd
6. PENEQUININE - gsrs, accessed September 9, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/353CX8CSHD
7. 151937-76-7|1-Cyclopentyl-1-phenyl-2-(quinuclidin-3-yloxy)ethanol hydrochloride, accessed September 9, 2025, https://www.bldpharm.com/products/151937-76-7.html
8. Penehyclidine hydrochloride (Penequinine hydrochloride ..., accessed September 9, 2025, https://www.medchemexpress.com/penehyclidine-hydrochloride.html
9. PENEHYCLIDINE HYDROCHLORIDE, accessed September 9, 2025, https://drugs.ncats.io/drug/0P1E1UF04I
10. Pleiotropic effects and pharmacological properties of penehyclidine hydrochloride, accessed September 9, 2025, https://www.tandfonline.com/doi/full/10.2147/DDDT.S177435
11. The advantages of penehyclidine hydrochloride over atropine in acute organophosphorus pesticide poisoning: A meta-analysis | Journal of Intensive Medicine - MedNexus, accessed September 9, 2025, https://mednexus.org/doi/10.1016/j.jointm.2022.07.006
12. CAS No. 87827-02-9 | MedChemExpress (MCE) Life Science, accessed September 9, 2025, https://www.medchemexpress.com/search.html?q=87827-02-9&ft=&fa=&fp=
13. What is Penehyclidine hydrochloride used for? - Patsnap Synapse, accessed September 9, 2025, https://synapse.patsnap.com/article/what-is-penehyclidine-hydrochloride-used-for
14. Pleiotropic effects and pharmacological properties of penehyclidine hydrochloride, accessed September 9, 2025, https://www.consensus.app/papers/pleiotropic-effects-and-pharmacological-properties-of-wang-ma/eb28f97083e75b6abab26dd8f646895f/
15. Penehyclidine hydrochloride: a potential drug for treating COPD by attenuating Toll-like receptors - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3490683/
16. The advantages of penehyclidine hydrochloride over atropine in acute organophosphorus pesticide poisoning: A meta-analysis - PMC - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10175710/
17. Efficacy and Safety of Penehyclidine ... - ASIDE Journals, accessed September 9, 2025, https://asidejournals.com/index.php/internal-medicine/article/download/47/35/1191
18. PENEQUININE - Inxight Drugs, accessed September 9, 2025, https://drugs.ncats.io/drug/353CX8CSHD
19. The Mechanism of Penehyclidine Hydrochloride and Its Effect on the Inflammatory Response of Lung Tissue in Rats with Chronic Obs - ScienceOpen, accessed September 9, 2025, https://www.scienceopen.com/document_file/da25f9e7-a7a5-451e-834f-388eb311e8cf/PubMedCentral/da25f9e7-a7a5-451e-834f-388eb311e8cf.pdf
20. Pleiotropic effects and pharmacological properties of penehyclidine ..., accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6181090/
21. Water Completed Phase 4 Trials for Postoperative Complications Prevention - DrugBank, accessed September 9, 2025, https://go.drugbank.com/drugs/DB09145/clinical_trials?conditions=DBCOND0031477&phase=4&purpose=prevention&status=completed
22. Search Results | DrugBank Online, accessed September 9, 2025, https://go.drugbank.com/unearth/q?c=_score&d=down&page=77&query=lidocaine+hydrochloride+epinephrine+bitartrate+infection+solution&search_type=drugs&searcher=drugs
23. Phencyclidine overdose: MedlinePlus Medical Encyclopedia, accessed September 9, 2025, https://medlineplus.gov/ency/article/002526.htm
24. Phencyclidine overdose - ADAM, accessed September 9, 2025, https://adamcertificationdemo.adam.com/content.aspx?productid=117&pid=1&gid=002526
25. Drug Interaction Report: dicyclomine, guaifenesin / phenylephrine - Drugs.com, accessed September 9, 2025, https://www.drugs.com/interactions-check.php?drug_list=875-0,1208-0&professional=1
26. Phencyclidine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 9, 2025, https://go.drugbank.com/drugs/DB03575
27. FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma, accessed September 9, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma
28. FDA Approval of Penpulimab Expands Treatment Options in Recurrent/Metastatic Non-Keratinizing NPC - OncLive, accessed September 9, 2025, https://www.onclive.com/view/fda-approval-of-penpulimab-expands-treatment-options-in-recurrent-metastatic-non-keratinizing-npc
29. PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU), accessed September 9, 2025, https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-fda-approval-sephiencetm-sepiapterin
30. FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma, accessed September 9, 2025, https://www.cancernetwork.com/view/fda-approves-penpulimab-in-non-keratinizing-nasopharyngeal-carcinoma
31. Browsing Drugs | DrugBank Online, accessed September 9, 2025, https://go.drugbank.com/drugs?approved=0&c=name&canada=0&d=up&eu=0&experimental=0&illicit=0&investigational=0&nutraceutical=0&page=406&us=0&withdrawn=0